Literature DB >> 23255917

Factors influencing the risk of recurrence in patients with esophageal carcinoma treated with surgery: A single institution analysis consisting of 1002 cases.

Yaping Xu1, Qixun Chen, Xinmin Yu, Ximing Zhou, Xiao Zheng, Weimin Mao.   

Abstract

The aim of this study was to identify the risk of recurrence in patients with thoracic esophageal squamous cell carcinoma (TESCC) treated with curative surgery. The retrospective analysis included 1002 consecutive patients with TESCC who had been treated with curative surgery in Zhejiang Cancer Hospital, China, between 2003 and 2008. Univariate and multivariate analyses using the Kaplan-Meier method and Cox proportional hazards model, respectively, were performed to identify the independent risk factors for locoregional recurrence and all the recurrence events. The 2-and 5-year recurrence rates were 39.0 and 59.2%, respectively. More than 85% of recurrences occurred within 36 months. The variables associated with a higher rate of recurrence in the univariate analysis were gender (male), length of tumor (≥5 cm), depth of invasion (deeper), lymph node metastasis (greater), histological grade (higher) and vessel involvement (positive). By multivariate analyses, gender (HR, 1.7; 95% CI, 1.2-2.5; P=0.002), depth of invasion (HR, 1.4; 95% CI, 1.2-1.6; P<0.001) and lymph node involvement (HR, 1.4; 95% CI, 1.3-1.5; P<0.001) were independent predictive factors of recurrence. Post-operative radiotherapy or chemotherapy did not significantly prolong failure-free survival (FFS), particularly in patients with early-stage disease. Information regarding the depth of primary tumor invasion and the number of lymph nodes involved may help in evaluating the recurrence risk in patients with TESCC treated with curative surgery. Further studies are required to clarify the correlation between recurrence and the different multidisciplinary treatment approaches.

Entities:  

Year:  2012        PMID: 23255917      PMCID: PMC3525364          DOI: 10.3892/ol.2012.1007

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  20 in total

1.  Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.

Authors:  Jeeyun Lee; Kyoung-Eun Lee; Young-Hyuck Im; Won Ki Kang; Keunchil Park; Kwhanmien Kim; Young Mog Shim
Journal:  Ann Thorac Surg       Date:  2005-10       Impact factor: 4.330

2.  Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery.

Authors:  S Dixit; M Tilston; W M Peter
Journal:  Med Oncol       Date:  2009-03-24       Impact factor: 3.064

3.  Pattern of recurrence after oesophageal resection for cancer: clinical implications.

Authors:  S Y Law; M Fok; J Wong
Journal:  Br J Surg       Date:  1996-01       Impact factor: 6.939

4.  Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus.

Authors:  M S Bhansali; H Fujita; T Kakegawa; H Yamana; T Ono; S Hikita; Y Toh; T Fujii; U Tou; K Shirouzu
Journal:  World J Surg       Date:  1997 Mar-Apr       Impact factor: 3.352

5.  Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals.

Authors:  Thomas W Rice; Valerie W Rusch; Hemant Ishwaran; Eugene H Blackstone
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

6.  Lymph node metastasis along the recurrent nerve chain is an indication for cervical lymph node dissection in thoracic esophageal cancer.

Authors:  H Shiozaki; M Yano; T Tsujinaka; M Inoue; S Tamura; Y Doki; T Yasuda; Y Fujiwara; M Monden
Journal:  Dis Esophagus       Date:  2001       Impact factor: 3.429

7.  Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.

Authors:  Atsushi Shiozaki; Hisakazu Yamagishi; Hirosumi Itoi; Hitoshi Fujiwara; Shojiro Kikuchi; Kazuma Okamoto; Daisuke Ichikawa; Nobuaki Fuji; Toshiya Ochiai; Teruhisa Sonoyama; Yuji Ueda
Journal:  Oncol Rep       Date:  2005-04       Impact factor: 3.906

8.  Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

Authors:  Nobutoshi Ando; Toshifumi Iizuka; Hiroko Ide; Kaoru Ishida; Masayuki Shinoda; Tadashi Nishimaki; Wataru Takiyama; Hiroshi Watanabe; Kaichi Isono; Norio Aoyama; Hiroyasu Makuuchi; Otsuo Tanaka; Hideaki Yamana; Shunji Ikeuchi; Toshiyuki Kabuto; Kagami Nagai; Yutaka Shimada; Yoshihide Kinjo; Haruhiko Fukuda
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

9.  Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study.

Authors:  Anil Heroor; Hiromasa Fujita; Susumu Sueyoshi; Toshiaki Tanaka; Uhi Toh; Takashi Mine; Hiroko Sasahara; Tomoya Sudo; Satoru Matono; Hideaki Yamana; Kazuo Shirouzu
Journal:  Dig Surg       Date:  2003       Impact factor: 2.588

10.  Prognostic factors after oesophagectomy and extended lymphadenectomy for squamous oesophageal cancer.

Authors:  H Osugi; M Takemura; N Takada; K Hirohashi; H Kinoshita; M Higashino
Journal:  Br J Surg       Date:  2002-07       Impact factor: 6.939

View more
  9 in total

1.  Clinical significance of ALDH1 combined with DAPI expression in patients with esophageal carcinoma.

Authors:  Hong Chen; Zhi-Qiang Zhang; Bin Zhao; Wen-Long Ning; Xue-Yan Wang; Fei Zhou
Journal:  Oncol Lett       Date:  2017-08-10       Impact factor: 2.967

2.  Single nucleotide polymorphism rs13042395 in the SLC52A3 gene as a biomarker for regional lymph node metastasis and relapse-free survival of esophageal squamous cell carcinoma patients.

Authors:  Hua-Zhen Tan; Zhi-Yong Wu; Jian-Yi Wu; Lin Long; Ji-Wei Jiao; Yu-Hui Peng; Yi-Wei Xu; Shan-Shan Li; Wei Wang; Jian-Jun Zhang; En-Min Li; Li-Yan Xu
Journal:  BMC Cancer       Date:  2016-07-29       Impact factor: 4.430

3.  Diagnostic value of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for preoperative lymph node metastasis of esophageal cancer: A meta-analysis.

Authors:  Jingfeng Hu; Dengyan Zhu; Yang Yang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

4.  Expression of miR-1304 in patients with esophageal carcinoma and risk factors for recurrence.

Authors:  Yun-Gang Luo; Li-Wei Duan; Xuan Ji; Wen-Yuan Jia; Yun Liu; Mao-Lei Sun; Guo-Min Liu
Journal:  World J Gastroenterol       Date:  2020-02-14       Impact factor: 5.742

5.  Can Lymphovascular Invasion be Predicted by Preoperative Contrast-Enhanced CT in Esophageal Squamous Cell Carcinoma?

Authors:  Wei Chen; Yating Wang; Genji Bai; Chunhong Hu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma.

Authors:  Tao Liu; Qianqian Yao; Hai Jin
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

7.  Contrast-Enhanced CT-Based Radiomics Analysis in Predicting Lymphovascular Invasion in Esophageal Squamous Cell Carcinoma.

Authors:  Yang Li; Meng Yu; Guangda Wang; Li Yang; Chongfei Ma; Mingbo Wang; Meng Yue; Mengdi Cong; Jialiang Ren; Gaofeng Shi
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

8.  Analysis of the causes of failure after radical surgery in patients with PT3N0M0 thoracic esophageal squamous cell carcinoma and consideration of postoperative radiotherapy.

Authors:  Wen-Bin Shen; Hong-Mei Gao; Shu-Chai Zhu; You-Mei Li; Shu-Guang Li; Jin-Rui Xu
Journal:  World J Surg Oncol       Date:  2017-10-25       Impact factor: 2.754

9.  Prognostic Factors for Recurrence in Esophageal Cancer Patients Treated With Neoadjuvant Therapy and Surgery: A Single-institution Analysis.

Authors:  Misbah Khan; Namra Urooj; Aamir Ali Syed; Shahid Khattak; Ather Kazmi; Mohammad I Ashraf; Sadaf Batool
Journal:  Cureus       Date:  2020-05-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.